Patent US2526523A successfully refreshed from Google Patents.
US5589451A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
Assignee: The University of Texas System
•
Filing: 1992-09-21
•
Granted: 1996-12-31
•
Expires: 2012-09-21
Abstract
Abstract The invention relates to the use of hepatocyte and keratinocyte growth factors for controlling the proliferation and motility of corneal cells in vivo and in vitro. It also relates to the use of these factors for maintaining the viability of the corneal cells during or after ocular surgery and during corneal preservation in storage medium prior to transplant. Polymerase chain reaction amplification has demonstrated that corneal epithelial and endothelial cells in vitro and ex vivo corneal epithelium produce messenger RNA coding for hepatocyte growth factor, hepatocyte growth factor receptor, keratinocyte growth factor, and keratinocyte growth factor receptor. Additionally, it was demonstrated that hepatocyte growth factor and keratinocyte growth factor stimulate the proliferation of corneal epithelial cells and corneal endothelial cells in vitro in a dose response manner.
Inventors
- 👤 Steven E. Wilson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:17
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1833
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
34 words
A method for promoting corneal cell proliferation or maintaining corneal cell viability in vivo comprising treating the corneal cells with an amount of hepatocyte growth factor to stimulate growth in a pharmaceutically acceptable composition.
Claim 2
Independent Claim
34 words
A method for promoting corneal cell proliferation or maintaining corneal cell viability in vivo comprising treating the corneal cells with an amount of hepatocyte growth factor to stimulate growth in a pharmaceutically acceptable composition.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein cells located on the corneal posterior surface are treated.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein cells located in corneal central regions are treated.
Claim 5
Dependent Claim
15 words
The method of claim 1 wherein the pharmaceutically acceptable composition further comprises keratinocyte growth factor.
Claim 6
Dependent Claim
20 words
The method of claim 4 wherein each growth factor is present between about 1 and about 50 nanograms per ml.
Claim 7
Dependent Claim
18 words
The method of claim 4 wherein each growth factor is present between about 1 and about 25 ng/ml.
Claim 8
Dependent Claim
18 words
The method of claim 4 wherein each growth factor is present between about 1 and about 10 ng/ml.
Claim 9
Dependent Claim
16 words
A pharmaceutical composition comprising hepatocyte growth factor and keratinocyte growth factor in a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
16 words
A pharmaceutical composition comprising hepatocyte growth factor and keratinocyte growth factor in a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
22 words
The composition of claim 8 wherein the amount of each growth factor is between about 1 and about 50 nanograms per ml.
Claim 12
Dependent Claim
20 words
The composition of claim 8 wherein the amount of either growth factor is between about 1 and about 25 ng/ml.
Claim 13
Dependent Claim
20 words
The composition of claim 8 wherein the amount of either growth factor is between about 1 to about 10 ng/ml.
Claim 14
Independent Claim
30 words
A method of suppressing hepatocyte growth factor stimulated corneal cell proliferation in culture comprising treating said corneal cells with an amount of calcium ion effective to suppress corneal cell proliferation.
Claim 15
Independent Claim
30 words
A method of suppressing hepatocyte growth factor stimulated corneal cell proliferation in culture comprising treating said corneal cells with an amount of calcium ion effective to suppress corneal cell proliferation.
Claim 16
Dependent Claim
17 words
The method of claim 12 wherein the corneal cells are treated with about 0.1 mM calcium ion.
References Cited (Backward Citations)
US5032575A
Cited
WO1990008781A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-12-31 | 2000-07-01 | 2000-12-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-12-31 | 2004-07-01 | 2004-12-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-12-31 | 2008-07-01 | 2008-12-31 | $7700.00 | Window Closed / Lapsed |